Links for fulltext
     (May Require Subscription)
Supplementary

Article: Tolerance of high-intensity focused ultrasound ablation in patients with hepatocellular carcinoma

TitleTolerance of high-intensity focused ultrasound ablation in patients with hepatocellular carcinoma
Authors
Issue Date2012
PublisherSpringer New York LLC. The Journal's web site is located at http://link.springer.de/link/service/journals/00268/
Citation
World Journal of Surgery, 2012, v. 36 n. 10, p. 2420-2427 How to Cite?
AbstractBACKGROUND: High-intensity focused ultrasound (HIFU) ablation is a relatively new, noninvasive way of ablation for treating hepatocellular carcinoma (HCC). Emerging evidence has shown that it is effective for the treatment of HCC, even in patients with poor liver function. There is currently no data on the safety limit of HIFU ablation in patients with cirrhosis. However, this information is vital for the selection of appropriate patients for the procedure. We analyzed HCC patients who had undergone HIFU ablation and determined the lower limit of liver function and other patient factors with which HCC patients can tolerate this treatment modality. METHODS: Preoperative variables of 100 patients who underwent HIFU ablation for HCC were analyzed to identify the risk factors in HIFU intolerance in terms of stress-induced complications. Factors that may contribute to postablation complications were compared. RESULTS: Thirteen (13 %) patients developed a total of 18 complications. Morbidity was mainly due to skin and subcutaneous tissue injuries (n = 9). Five patients had first-degree skin burn, one had second-degree skin burn, and three had third-degree skin burn. Four complications were grade 3a in the Clavien classification and 14 were below this grade. Univariate analysis showed that age (p = 0.022) was the only independent factor in HIFU intolerance. CONCLUSIONS: HIFU ablation is generally well tolerated in HCC patients with cirrhosis. It is safe for Child-Pugh A and B patients and selected Child-Pugh C patients. With this new modality, HCC patients who were deemed unsalvageable by other surgical means in the past because of simultaneous Child-Pugh B or C disease now have a new hope.
Persistent Identifierhttp://hdl.handle.net/10722/163752
ISSN
2015 Impact Factor: 2.523
2015 SCImago Journal Rankings: 1.375
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorCheung, TTen_US
dc.contributor.authorChu, FSKen_US
dc.contributor.authorJenkins, CRen_US
dc.contributor.authorTsang, DSFen_US
dc.contributor.authorChok, KSHen_US
dc.contributor.authorChan, ACYen_US
dc.contributor.authorYau, TCCen_US
dc.contributor.authorChan, SCen_US
dc.contributor.authorPoon, RTPen_US
dc.contributor.authorLo, CMen_US
dc.contributor.authorFan, STen_US
dc.date.accessioned2012-09-20T07:50:53Z-
dc.date.available2012-09-20T07:50:53Z-
dc.date.issued2012en_US
dc.identifier.citationWorld Journal of Surgery, 2012, v. 36 n. 10, p. 2420-2427en_US
dc.identifier.issn0364-2313-
dc.identifier.urihttp://hdl.handle.net/10722/163752-
dc.description.abstractBACKGROUND: High-intensity focused ultrasound (HIFU) ablation is a relatively new, noninvasive way of ablation for treating hepatocellular carcinoma (HCC). Emerging evidence has shown that it is effective for the treatment of HCC, even in patients with poor liver function. There is currently no data on the safety limit of HIFU ablation in patients with cirrhosis. However, this information is vital for the selection of appropriate patients for the procedure. We analyzed HCC patients who had undergone HIFU ablation and determined the lower limit of liver function and other patient factors with which HCC patients can tolerate this treatment modality. METHODS: Preoperative variables of 100 patients who underwent HIFU ablation for HCC were analyzed to identify the risk factors in HIFU intolerance in terms of stress-induced complications. Factors that may contribute to postablation complications were compared. RESULTS: Thirteen (13 %) patients developed a total of 18 complications. Morbidity was mainly due to skin and subcutaneous tissue injuries (n = 9). Five patients had first-degree skin burn, one had second-degree skin burn, and three had third-degree skin burn. Four complications were grade 3a in the Clavien classification and 14 were below this grade. Univariate analysis showed that age (p = 0.022) was the only independent factor in HIFU intolerance. CONCLUSIONS: HIFU ablation is generally well tolerated in HCC patients with cirrhosis. It is safe for Child-Pugh A and B patients and selected Child-Pugh C patients. With this new modality, HCC patients who were deemed unsalvageable by other surgical means in the past because of simultaneous Child-Pugh B or C disease now have a new hope.-
dc.languageengen_US
dc.publisherSpringer New York LLC. The Journal's web site is located at http://link.springer.de/link/service/journals/00268/-
dc.relation.ispartofWorld Journal of Surgeryen_US
dc.rightsThe original publication is available at www.springerlink.com-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.titleTolerance of high-intensity focused ultrasound ablation in patients with hepatocellular carcinomaen_US
dc.typeArticleen_US
dc.identifier.emailCheung, TT: cheung68@hku.hken_US
dc.identifier.emailJenkins, CR: cjenkins@hkucc.hku.hken_US
dc.identifier.emailChan, ACY: acchan@hku.hken_US
dc.identifier.emailYau, TCC: tyaucc@hku.hken_US
dc.identifier.emailChan, SC: chanlsc@hkucc.hku.hken_US
dc.identifier.emailPoon, RTP: poontp@hku.hken_US
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_US
dc.identifier.emailFan, ST: stfan@hku.hken_US
dc.identifier.authorityJenkins, CR=rp01583en_US
dc.identifier.authorityChan, ACY=rp00310en_US
dc.identifier.authorityYau, TCC=rp01466en_US
dc.identifier.authorityChan, SC=rp01568en_US
dc.identifier.authorityPoon, RTP=rp00446en_US
dc.identifier.authorityLo, CM=rp00412en_US
dc.identifier.authorityFan, ST=rp00355en_US
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1007/s00268-012-1660-7-
dc.identifier.pmid22699746-
dc.identifier.pmcidPMC3465545-
dc.identifier.scopuseid_2-s2.0-84867818136-
dc.identifier.hkuros211052en_US
dc.identifier.volume36en_US
dc.identifier.issue10-
dc.identifier.spage2420-
dc.identifier.epage2427-
dc.identifier.isiWOS:000309559800019-
dc.publisher.placeUnited States-
dc.identifier.citeulike10803538-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats